Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Valeant

- PMLiVE

Shire warms to Takeda’s latest offer, extending deadline

The new offer is £5 per share higher than Takeda’s opening bid

- PMLiVE

Pfizer takes aim at UK’s health tech industry

Offers start-ups a share of a £56k grant

Shire Basingstoke

Morning brief: Takeda closes in on $64bn merger, GSK unveils team, and more

A rapid run-down of news in pharma, biotech and healthcare

Uncertainty, austerity and Brexit

What does it mean for the life science sector?

- PMLiVE

Will Shire agree to extend Takeda takeover talks?

UK rules mean Shire must agree to extend deadline

- PMLiVE

New centre aims to Catapult UK into cell and gene therapy lead

The UK is hoping to cement its lead as a world leader in cell and gene therapy manufacturing thanks to a new ‘Catapult’ centre opened today.

- PMLiVE

Shire rebuffs Takeda bids, as Allergan bows out

Allergan doesn’t intend to make a formal offer following a dip in its share prices

Brexit Means Brexit

The differential destinations of post-Brexit pharma

- PMLiVE

Shire offloads oncology unit to Servier for $2.4bn

The French drugmaker will also acquire Oncaspar and Onivyde as part of the deal

Sanofi reception

NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

Dupixent is still too expensive despite discount, says the UK’s cost effectiveness body

- PMLiVE

EMA starts rapid review of Shire’s HAE antibody

The EU medicines regulator is expected to make a verdict in 150 days

- PMLiVE

Takeda mulls bid for Irish biopharma Shire

The Japanese pharma firm must make a formal offer by 25 April

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links